SG11201808678QA - Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions - Google Patents

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions

Info

Publication number
SG11201808678QA
SG11201808678QA SG11201808678QA SG11201808678QA SG11201808678QA SG 11201808678Q A SG11201808678Q A SG 11201808678QA SG 11201808678Q A SG11201808678Q A SG 11201808678QA SG 11201808678Q A SG11201808678Q A SG 11201808678QA SG 11201808678Q A SG11201808678Q A SG 11201808678QA
Authority
SG
Singapore
Prior art keywords
bristol
myers squibb
company
connecticut
wallingford
Prior art date
Application number
SG11201808678QA
Inventor
Michael Matthew Miller
Martin Patrick Allen
Ling Li
Michael S Bowsher
Eric P Gillis
Eric Mull
Qian Zhao
Li-Qiang Sun
David R Langley
Paul Michael Scola
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201808678QA publication Critical patent/SG11201808678QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M11111011101 11111111110101111101110101111111110011111110111111111110111111 International Bureau 0.. .... .. (10) International Publication Number ..... ...,/ (43) International Publication Date WO 2017/176608 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: ers Squibb Company, 5 Research Parkway, Wallingford, CO7K 7/54 (2006.01) A61P 31/00 (2006.01) Connecticut 06492 (US). LANGLEY, David R.; c/o Bris- CO7K 7/64 (2006.01) A61K 38/12 (2006.01) tol-Myers Squibb Company, 5 Research Parkway, Walling- A61P 35/00 (2006.01) ford, Connecticut 06492 (US). SCOLA, Paul Michael; c/o Bristol-Myers Squibb Company, 5 Research Parkway, (21) International Application Number: Wallingford, Connecticut 06492 (US). PCT/US2017/025677 (74) Agents: MINGO, Pamela A. et al.; Bristol-Myers Squibb (22) International Filing Date: Company, Route 206 and Province Line Road, Princeton, 3 April 2017 (03.04.2017) New Jersey 08543 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 62/318,417 5 April 2016 (05.04.2016) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 15/475,227 31 March 2017 (31.03.2017) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, [US/US]; Route 206 and Province Line Road, Princeton, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, New Jersey 08543 (US). NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (72) Inventors: MILLER, Michael Matthew; c/o Bristol-My- TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ers Squibb Company, Route 206 and Province Line Road, ZA, ZM, ZW. Princeton, New Jersey 08543 (US). ALLEN, Martin Patrick; c/o Bristol-Myers Squibb Company, Route 206 (84) Designated States (unless otherwise indicated, for every and Province Line Road, Princeton, New Jersey 08543 kind of regional protection available): ARIPO (BW, GH, (US). LI, Ling; c/o Bristol-Myers Squibb Company, Route GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 206 and Province Line Road, Princeton, New Jersey 08543 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (US). BOWSHER, Michael S.; c/o Bristol-Myers Squibb TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Company, 5 Research Parkway, Wallingford, Connecticut DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 06492 (US). GILLIS, Eric P.; c/o Bristol-Myers Squibb LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Company, 5 Research Parkway, Wallingford, Connecticut SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 06492 (US). MULL, Eric; c/o Bristol-Myers Squibb Com- GW, KM, ML, MR, NE, SN, TD, TG). pany, 5 Research Parkway, Wallingford, Connecticut Declarations under Rule 4.17: 06492 (US). ZHAO, Qian; 93 Hintz Drive, Wallingford, — as to applicant's entitlement to apply for and be granted a Connecticut 06492 (US). SUN, Li-Qiang; c/o Bristol-My- patent (Rule 4.1700) [Continued on next page] Title: MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS = (54) R . Rt 0 R RI NN O R 5 Cr). Il R . a R1B(~ R z R14 R. . 4 „ GC © Rz z R . ,19 R. 15 NI. IN R . Il IN 1-1 (57) : The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L 1/CD80 0 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. ” wherein: A is selected from a bond. O WO 2017/176608 Al MIDEDIMOMONIIMOIDEOMOIHHIMOOMODEVOIMIE • — as to the applicant's entitlement to claim the priority the earlier application (Rule 4.17(iii)) of '\"\"'\"\"' — with international search report (Art. 21(3)) — of inventorship (Rule 4.17(iv)) — with sequence listing part of description (Rule 5.2(a))
SG11201808678QA 2016-04-05 2017-04-03 Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions SG11201808678QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318417P 2016-04-05 2016-04-05
US15/475,227 US10358463B2 (en) 2016-04-05 2017-03-31 Immunomodulators
PCT/US2017/025677 WO2017176608A1 (en) 2016-04-05 2017-04-03 Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions

Publications (1)

Publication Number Publication Date
SG11201808678QA true SG11201808678QA (en) 2018-11-29

Family

ID=59960204

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808678QA SG11201808678QA (en) 2016-04-05 2017-04-03 Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions

Country Status (17)

Country Link
US (1) US10358463B2 (en)
EP (1) EP3440097A1 (en)
JP (1) JP7122255B2 (en)
KR (1) KR102548798B1 (en)
CN (1) CN109311943A (en)
AR (1) AR108186A1 (en)
AU (1) AU2017246216A1 (en)
BR (1) BR112018070377A2 (en)
CA (1) CA3020300A1 (en)
EA (1) EA201892243A1 (en)
IL (1) IL262126A (en)
MA (1) MA43774A (en)
MX (1) MX2018012039A (en)
SG (1) SG11201808678QA (en)
TW (1) TW201738260A (en)
UY (1) UY37194A (en)
WO (1) WO2017176608A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) * 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
EA038019B1 (en) 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Pet-imaging immunomodulators
MA46535A (en) 2016-10-14 2019-08-21 Prec Biosciences Inc SPECIFIC MODIFIED MEGANUCLEASES OF RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
JP7206222B2 (en) * 2017-06-23 2023-01-17 ブリストル－マイヤーズ スクイブ カンパニー Immunomodulators that act as antagonists of PD-1
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
MX2020008138A (en) * 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Parenteral formulations and uses thereof.
TWI796596B (en) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd-1/pd-l1 inhibitors
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
JP7296398B2 (en) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． 3'3'-cyclic dinucleotide
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TW201945388A (en) 2018-04-12 2019-12-01 美商精密生物科學公司 Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
BR112020024404A2 (en) 2018-05-31 2021-03-02 Ono Pharmaceutical Co., Ltd. biomarkers to determine the effectiveness of immune checkpoint inhibitors
TW202017569A (en) 2018-05-31 2020-05-16 美商佩樂敦治療公司 Compositions and methods for inhibiting cd73
KR20230159715A (en) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
TW202028212A (en) 2018-10-11 2020-08-01 日商小野藥品工業股份有限公司 Sting agonist compound
KR102635333B1 (en) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 PD-1/PD-L1 inhibitors
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113891748A (en) 2019-03-28 2022-01-04 百时美施贵宝公司 Method for treating tumors
KR20210146348A (en) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
TWI751517B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
JP2022533233A (en) * 2019-05-21 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Immunomodulator
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
US20220283167A1 (en) 2019-08-05 2022-09-08 Ono Pharmaceutical Co., Ltd. Biomarkers for determining the efficacy of immune checkpoint inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CA3153777A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
CR20220129A (en) 2019-09-30 2022-05-06 Gilead Sciences Inc Hbv vaccines and methods treating hbv
CA3160479A1 (en) 2019-11-08 2021-05-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
KR20220122752A (en) * 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 immunomodulators
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN115362166A (en) * 2020-03-30 2022-11-18 百时美施贵宝公司 Immunomodulator
JPWO2021205631A1 (en) 2020-04-10 2021-10-14
EP4134098A4 (en) 2020-04-10 2024-05-15 Ono Pharmaceutical Co Method of cancer therapy
CN113754736A (en) * 2020-06-02 2021-12-07 南京礼威生物医药有限公司 Hydrazide structure-containing PD-L1 cyclopeptide inhibitor
CN111961117B (en) * 2020-08-19 2022-03-11 中山大学 Cyclopeptide compound and application thereof
JP2023540255A (en) 2020-08-28 2023-09-22 ブリストル－マイヤーズ スクイブ カンパニー LAG-3 antagonist therapy for hepatocellular carcinoma
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
KR20240005700A (en) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy
TW202310852A (en) 2021-05-13 2023-03-16 美商基利科學股份有限公司 Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
KR20240019236A (en) * 2021-06-09 2024-02-14 브리스톨-마이어스 스큅 컴퍼니 Cyclic peptide immunomodulator
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
TW202317200A (en) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Combination mcl-1 inhibitors with anti-body drug conjugates
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023196964A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine learning identification, classification, and quantification of tertiary lymphoid structures

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
KR20020063230A (en) * 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 Novel lipopeptides as antibacterial agents
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (en) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
EP3012265B1 (en) 2007-03-26 2017-06-28 The University of Tokyo Process for synthesizing cyclic peptide compound
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (en) 2010-09-09 2015-11-18 国立大学法人 東京大学 Translational construction and search for active species of special peptide compound library containing N-methylamino acid and other special amino acids
WO2012074130A1 (en) 2010-12-03 2012-06-07 国立大学法人東京大学 Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
JP6047231B2 (en) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β-hairpin peptidomimetics
JP2013253842A (en) 2012-06-06 2013-12-19 Univ Of Tokyo Screening method for peptide connected to target molecule depending on ph
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
RU2701378C2 (en) 2013-03-15 2019-09-26 Дженентек, Инк. Biomarkers and methods of treating associated with pd-1 and pd-l1 conditions
CA2922982A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
MX2017003201A (en) 2014-09-11 2017-05-23 Bristol Myers Squibb Co Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions.
US9732119B2 (en) * 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
EA038019B1 (en) 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Pet-imaging immunomodulators

Also Published As

Publication number Publication date
JP7122255B2 (en) 2022-08-19
UY37194A (en) 2017-10-31
BR112018070377A2 (en) 2019-02-05
TW201738260A (en) 2017-11-01
US20170283463A1 (en) 2017-10-05
KR102548798B1 (en) 2023-06-27
MA43774A (en) 2018-11-28
EA201892243A1 (en) 2019-03-29
CN109311943A (en) 2019-02-05
US10358463B2 (en) 2019-07-23
EP3440097A1 (en) 2019-02-13
JP2019513734A (en) 2019-05-30
AR108186A1 (en) 2018-07-25
MX2018012039A (en) 2019-01-14
KR20180132775A (en) 2018-12-12
AU2017246216A1 (en) 2018-11-22
IL262126A (en) 2018-11-29
WO2017176608A1 (en) 2017-10-12
CA3020300A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201807426WA (en) Immunomodulators
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201903908PA (en) Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
SG11201808014SA (en) Compositions, devices, and methods for cell separation
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909011PA (en) Niraparib compositions
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201408261UA (en) Syringe
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201407662WA (en) Process for the preparation of treprostinil and derivatives thereof
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201900904PA (en) Methods for cross coupling
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201407372UA (en) Nampt inhibitors
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins